Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1YVZT)

Drug Name

Rituximab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Central nervous system non-hodgkin lymphoma		Approved	[1]
Eosinophilic granulomatosis with polyangiitis	4A44.A2	Approved	[2]
Hepatosplenic T-cell lymphoma		Approved	[3]
Idiopathic thrombocytopenic purpura	3B64.10	Approved	[4]
Large granular lymphocytic leukemia	2A90.1	Approved	[5]
Leukemia		Approved	[6]
Lupus nephritis	4A40.0Y	Approved	[7]
Lymphoproliferative syndrome		Approved	[8]
Lymphosarcoma		Approved	[9]
MALT lymphoma		Approved	[10]
Nodal marginal zone lymphoma	2A85.0	Approved	[11]
Non-hodgkin lymphoma	2B33.5	Approved	[12]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified		Approved	[13]
Prolymphocytic leukaemia	2A82.1	Approved	[14]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[15]
Small intestine lymphoma		Approved	[16]
Small lymphocytic lymphoma	2A82.0	Approved	[17]
Splenic marginal zone lymphoma		Approved	[18]
Testicular lymphoma		Approved	[19]
Thrombotic thrombocytopenic purpura	3B64.14	Approved	[20]
Waldenstrom macroglobulinemia	2A85.4	Approved	[21]
Pemphigus vulgaris	EB40	Phase 3	[22]
Haematological malignancy	2B33.Y	Phase 1	[23]
B-cell neoplasm		Investigative	[24]

Cross-matching ID

TTD Drug ID: DM1YVZT

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[27]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[28]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[29]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[30]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[31]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[30]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[32]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[33]
Ocrelizumab	DMEZ2KH	Diffuse large B-cell lymphoma	2A81	Approved	[34]
Glofitamab	DM45HT6	Diffuse large B-cell lymphoma	2A81	Approved	[35]
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[27]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[28]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[29]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[30]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[31]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[30]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[32]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[33]
Ocrelizumab	DMEZ2KH	Diffuse large B-cell lymphoma	2A81	Approved	[34]
Glofitamab	DM45HT6	Diffuse large B-cell lymphoma	2A81	Approved	[35]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[36]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[37]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[38]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[39]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[40]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[41]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[42]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[44]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[42]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[25]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Drug Response	[26]

------------------------------------------------------------------------------------

References

1	How we treat primary central nervous system lymphoma. ESMO Open. 2021 Aug;6(4):100213.
2	Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 Oct;68(4):430-436.
3	Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. Diagn Pathol. 2014 Mar 12;9:58.
4	Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
5	Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
6	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.
7	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
8	Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
9	Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
10	Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022 Dec 23;12(1):120.
11	Nodal marginal zone lymphoma. Leuk Lymphoma. 2014 Jun;55(6):1240-50.
12	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
13	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
14	B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228.
15	Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2023 Mar;64(3):586-596.
16	Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24806.
17	Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043.
18	Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148.
19	First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72.
20	Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536.
21	Waldenstr?m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-358.
22	ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
24	Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296.
25	[Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
26	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
27	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
29	Clinical pipeline report, company report or official report of Genmab.
30	Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
31	The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
32	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
33	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
34	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
35	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970.
36	Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
37	Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
38	Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
39	Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
40	Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
41	ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
42	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
43	Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
44	Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.